Oryzon Genomics (MEX:ORYN) EBIT per Share: MXN-3.27 (TTM As of Mar. 2026)


MEX:ORYN Oryzon Genomics SA MEX:ORYN
31 GF Score
Price MXN48.59
View Full Analysis

What is Oryzon Genomics EBIT per Share?

Oryzon Genomics MEX:ORYN 31 EBIT per Share is MXN-3.27 as of Mar. 2026. GuruFocus rates MEX:ORYN with a GF Score™ of 31/100. Among 1,185 Biotechnology companies, Oryzon Genomics ranks worse than 57.47% on this metric.

Oryzon Genomics's EBIT per Share for the three months ended in Mar. 2026 was MXN-1.55. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-3.27.

During the past 3 years, the average EBIT per Share Growth Rate was 9.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was 7.70% per year. During the past 10 years, the average EBIT per Share Growth Rate was -7.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Oryzon Genomics's EBIT per Share or its related term are showing as below:

MEX:ORYN' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -122.4   Med: 5.85   Max: 20.2
Current: 9.2

During the past 12 years, the highest 3-Year average EBIT per Share Growth Rate of Oryzon Genomics was 20.20% per year. The lowest was -122.40% per year. And the median was 5.85% per year.

MEX:ORYN's 3-Year EBIT Growth Rate is ranked worse than
57.47% of 1185 companies
in the Biotechnology industry
Industry Median: 15.4 vs MEX:ORYN: 9.20

Oryzon Genomics's EBIT for the three months ended in Mar. 2026 was MXN-120.21 Mil.

Oryzon Genomics  (MEX:ORYN) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Oryzon Genomics EBIT per Share Related Terms

Oryzon Genomics EBIT per Share Historical Data

* Premium members only.

The historical data trend for Oryzon Genomics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oryzon Genomics EBIT per Share Chart

Oryzon Genomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.96 -2.03 -1.30 -1.43 -1.36

Oryzon Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.19 0.19 -1.24 -0.67 -1.55
MEX:ORYN
31GF Score
Oryzon Genomics SA MEX:ORYN
EBIT per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Oryzon Genomics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Oryzon Genomics's EBIT per Share for the fiscal year that ended in Dec. 2025 is calculated as

EBIT per Share(A: Dec. 2025 )
=EBIT/Shares Outstanding (Diluted Average)
=-105.549/77.513
=-1.36

Oryzon Genomics's EBIT per Share for the quarter that ended in Mar. 2026 is calculated as

EBIT per Share(Q: Mar. 2026 )
=EBIT/Shares Outstanding (Diluted Average)
=-120.206/77.513
=-1.55

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-3.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT per Share →
What does a EBIT per Share of MXN-3.27 mean?
Oryzon Genomics (MEX:ORYN) has a EBIT per Share of MXN-3.27 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Oryzon Genomics and its competitors. According to the industry distribution chart, Oryzon Genomics ranks #681 out of 1185 companies in the Biotechnology industry, placing it in the top 57.5%.
Is Oryzon Genomics' EBIT per Share too high?
Oryzon Genomics' current EBIT per Share is MXN-3.27. Based on the distribution chart, Oryzon Genomics ranks #681 out of 1185 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Oryzon Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Oryzon Genomics' EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Oryzon Genomics ranks #681 out of 1185 companies for EBIT per Share. This places Oryzon Genomics in the lower half of its industry. The industry median EBIT per Share is 15.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.40, based on 1,185 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Oryzon Genomics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oryzon Genomics's current EBIT per Share is MXN-3.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oryzon Genomics stock overvalued right now?
Oryzon Genomics (MEX:ORYN) has a current EBIT per Share of MXN-3.27. The current EBIT per Share is MXN-3.27. Oryzon Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Oryzon Genomics (MEX:ORYN), the current EBIT per Share is MXN-3.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oryzon Genomics Business Description

Address Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.
31GF Score

Get the complete analysis for MEX:ORYN

EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN48.59
Price